Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Inflation-weary Americans are still spending money every month, but the April numbers show they’re starting to cut back on a few types of expensive purchases.
You don’t have to be an Olympic-level athlete to wear On’s shoes or apparel, but the company will use the 2024 games to continue growing its footprint.
Companies are making money, the economy is cooling down, and a rate cut or two possible by the fall? It might be time to break out the cautious optimism.
Fed Chair Jerome Powell reported that rates would likely remain elevated due to sticky inflation. Zillow breaks down how this could impact the housing market.
